Challenges and Opportunities in Drug Delivery Research

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Current Issues in Molecular Biology cimb	2.8	2.9	1999	15.8 Days	CHF 2200
Molecules molecules	4.2	7.4	1996	15.1 Days	CHF 2700
Pharmaceuticals pharmaceuticals	4.3	6.1	2004	13.9 Days	CHF 2900
Pharmaceutics pharmaceutics	4.9	7.9	2009	15.5 Days	CHF 2900
Scientia Pharmaceutica scipharm	2.3	4.6	1930	26.1 Days	CHF 1000

29 pages, 1152 KiB

Open AccessReview

Physicochemical Characteristics of Cardiological Drugs and Practical Recommendations for Intravenous Administration: A Systematic Review

by Massimiliano Quici, Elena Martini, Davide Giustivi, Maria Calloni, Chiara Cogliati, Alba Taino, Antonella Foschi, Andrea Gori, Paolo Zappa, Francesco Casella, Arianna Bartoli, Leyla La Cava, Alessia Meschia, Rosita Celano, Francesco Urso, Dario Cattaneo and Antonio Gidaro

Sci. Pharm. 2025, 93(1), 13; https://doi.org/10.3390/scipharm93010013 - 12 Mar 2025

Viewed by 1383

Abstract

Most cardiological drugs need intravenous administration to have a fast effect in an emergency. Intravenous administration is linked to complications, such as tissue infiltration and thrombophlebitis. Aiming to supply an effective tool for the development of appropriate policies, this systematic review provides practical [...] Read more.

Most cardiological drugs need intravenous administration to have a fast effect in an emergency. Intravenous administration is linked to complications, such as tissue infiltration and thrombophlebitis. Aiming to supply an effective tool for the development of appropriate policies, this systematic review provides practical recommendations about the diluent, pH, osmolarity, dosage, vesicant properties, and phlebitis rate of the most commonly used cardiological drugs evaluated in randomized controlled trials (RCTs) till 31 August 2024. The authors searched for available IV cardiological drugs in RCTs in PUBMED EMBASE^®, EBSCO-CINAHL^®, and Cochrane Controlled Clinical trials. Drugs’ chemical features were obtained online, in drug data sheets, and in scientific papers, establishing that the drugs with a pH of <5 or >9, an osmolarity > 600 mOsm/L, and a high incidence of phlebitis reported in the literature, as well as vesicant drugs, require utmost caution during administration. A total of 857 papers were evaluated and 316 studies were included. A total of 84 cardiological drugs were identified, of which only 31 (37%) can be safely infused via a peripheral route. Thrombolytics and anticoagulants are considered the safest classes of drugs, with only one drug flagged as a “red flag” medication. However, a higher percentage of drugs in other categories meet the “red flag” criteria, including antiarrhythmics (52%), antiplatelet agents (67%), diuretics (67%), antihypertensives (70%), other drugs (77%), and vasoconstrictors and inotropics (89%). Understanding the physicochemical properties of cardiological drugs is essential for significantly improving patient safety and preventing administration errors and local side effects. Full article

(This article belongs to the Topic Challenges and Opportunities in Drug Delivery Research)

► Show Figures

Figure 1

19 pages, 19210 KiB

Open AccessArticle

Development for Probiotics Based Insulin Delivery System

by Byung Chull An, Jusung Lee, Hye Yeon Won, Yongku Ryu and Myung Jun Chung

Curr. Issues Mol. Biol. 2025, 47(3), 137; https://doi.org/10.3390/cimb47030137 - 21 Feb 2025

Viewed by 538

Abstract

Probiotics show beneficial effects on diabetes mellitus (DM). If probiotics can secrete the recombinant insulins that may help suppress DM development, then it would likely have very few adverse side effects. To produce insulin analogs in bacteria, recombinant insulin (insulin-CBT1) should be the [...] Read more.

Probiotics show beneficial effects on diabetes mellitus (DM). If probiotics can secrete the recombinant insulins that may help suppress DM development, then it would likely have very few adverse side effects. To produce insulin analogs in bacteria, recombinant insulin (insulin-CBT1) should be the single-chain insulin (SCI) similar to proinsulin. However, insulin-CBT1 should allow the protein to activate insulin receptors directly without the need for proteolytic cleavage. In this study, we evaluated the effect of the flexible linker peptide on the physical and structural characteristics of insulin-CBT1 compared with commercial insulin (c-insulin). In the results, the linker peptide had marked effects on polarity and structure by increasing the α-helix content (19.3%→25.6%). Furthermore, insulin-CBT1 induced MIN6 proliferation 1.75-fold more than c-insulin, whereas differentiation and glucose uptake rates by 3T3-L1 were 39% and 15% lower, respectively. The biological anti-diabetes properties of insulin-CBT1 were well evaluated compared with c-insulin. Furthermore, we first suggest a special method for oral administration of insulin-CBT 1 without damage to the digestive tract. We developed an insulin-CBT1 delivery system using Pediococcus pentosaceus (PP), which has been reported as a potential bacteria in DM. First, insulin-CBT1 was harbored in pCBT2-24, which verified the expression and secretion vector system of PP. We finally confirmed that PP-insulin-CBT1 successfully secreted insulin-CBT1 proteins to culture media. These results presented herein open up new avenues to developing therapeutic options for DM. Full article

(This article belongs to the Topic Challenges and Opportunities in Drug Delivery Research)

► Show Figures

Figure 1

20 pages, 7172 KiB

Open AccessEditor’s ChoiceArticle

Eutectogel-Based Drug Delivery: An Innovative Approach for Atenolol Administration

by Roberta Cassano, Roberta Sole, Carlo Siciliano, Noemi Baldino, Olga Mileti, Debora Procopio, Federica Curcio, Gabriella Calviello, Simona Serini, Sonia Trombino and Maria Luisa Di Gioia

Pharmaceutics 2024, 16(12), 1552; https://doi.org/10.3390/pharmaceutics16121552 - 4 Dec 2024

Cited by 1 | Viewed by 1380

Abstract

Background: Hypertension affects 32% of adults worldwide, leading to a significant global consumption of cardiovascular medications. Atenolol, a β-adrenergic receptor blocker, is widely prescribed for cardiovascular diseases such as hypertension, angina pectoris, and myocardial infarction. According to the Biopharmaceutics Classification System (BCS), atenolol [...] Read more.

Background: Hypertension affects 32% of adults worldwide, leading to a significant global consumption of cardiovascular medications. Atenolol, a β-adrenergic receptor blocker, is widely prescribed for cardiovascular diseases such as hypertension, angina pectoris, and myocardial infarction. According to the Biopharmaceutics Classification System (BCS), atenolol belongs to Class III, characterized by high solubility but low permeability. Currently, atenolol is commercially available in oral formulations. Increasing attention is being directed towards developing cost-effective transdermal delivery systems, due to their ease of use and better patient compliance. Eutectogels represent next-generation systems that are attracting great interest in the scientific community. Typically obtained from deep eutectic solvents (DESs) combined with gelling agents, these systems exhibit unique properties due to the intrinsic characteristics of DESs. Methods: In this study, a DES based on choline chloride as a hydrogen bond acceptor (HBA) and propylene glycol as a hydrogen bond donor (HBD) was explored to enhance the topical delivery of atenolol. The solubility of atenolol in the DES was evaluated using spectroscopic and thermodynamic measurements which confirmed the formation of hydrogen bonds between the drug and DES components. Additionally, the safety of the DES was assessed in a cell viability assay. Subsequently, we formulated eutectogels with different concentrations using animal gelatin and Tego Carbomer 140, and characterized these formulations through rheological measurements, swelling percentage, and permeation studies with Franz cells. Results: These novel eutectogels exhibit superior performance over conventional hydrogels, with a release rate of approximately 86% and 51% for Carbomer- and gelatin-based eutectogels, respectively. In contrast, comparable hydrogels released only about 27% and 35%. Conclusions: These findings underscore the promising potential of eutectogels for the transdermal delivery of atenolol. Full article

(This article belongs to the Topic Challenges and Opportunities in Drug Delivery Research)

► Show Figures

Figure 1

17 pages, 2866 KiB

Open AccessArticle

Development of a pH-Sensitive Nanoparticle via Self-Assembly of Fucoidan and Protamine for the Oral Delivery of Insulin

by Hongying Cai, Fanxing Yong, Rui Li, Jianping Chen, Xiaofei Liu, Bingbing Song, Zhuo Wang, Qiaoli Zhao and Saiyi Zhong

Pharmaceutics 2024, 16(10), 1323; https://doi.org/10.3390/pharmaceutics16101323 - 11 Oct 2024

Viewed by 1440

Abstract

Objectives: Oral insulin delivery has received much attention over the past 20 years due to its high compliance. The aim of this study is to prepare nanoparticles for the oral delivery of insulin; Methods: Fucoidan and protamine were used to prepare [...] Read more.

Objectives: Oral insulin delivery has received much attention over the past 20 years due to its high compliance. The aim of this study is to prepare nanoparticles for the oral delivery of insulin; Methods: Fucoidan and protamine were used to prepare a pH-sensitive nanoparticle via self-assembly. The secondary structure and in vitro stability of the nanoparticles were characterized using FTIR, XRD, ITC, and TEM. the nanoparticles had a controlled release effect on insulin in simulated intestinal fluid. The pre-liminary therapeutic effect on high-fat-fed type 2 diabetic mice; Results: When the fucoidan/protamine mass ratio was 10:3 (w/w), the particle size and zeta potential were 140.83 ± 1.64 nm and −48.13 ± 0.61 mV.The encapsulation efficiency of insulin was 62.97 ± 0.59%. The preliminary therapeutic effect on type 2 diabetic mice showed that the fasting blood glucose of diabetic mice decreased from 10.28 ± 0.88 mmol/L to 9.22 ± 0.64 mmol/L, the area under the curve value of oral glucose tolerance test was reduced by 11.70%, and the insulin se-cretion of diabetic mice was increased by 13.3%; Conclusions: The nanoparticles were prepared successfully by self-assembly. The empty and insulin-loaded nanoparticles remained stable in simulated gastric fluid, and the nanoparticles had a controlled release effect on insulin in simulated intestinal fluid. Moreover, insulin-loaded nanoparticles could relieve on type 2 diabetic mice. Full article

(This article belongs to the Topic Challenges and Opportunities in Drug Delivery Research)

► Show Figures

Figure 1

26 pages, 4021 KiB

Open AccessReview

Recent Advances in Ocular Drug Delivery: Insights into Lyotropic Liquid Crystals

by Samer Adwan, Madeiha Qasmieh, Faisal Al-Akayleh and Ahmed Saad Abdulbari Ali Agha

Pharmaceuticals 2024, 17(10), 1315; https://doi.org/10.3390/ph17101315 - 2 Oct 2024

Cited by 3 | Viewed by 3559

Abstract

Background/Objectives: This review examines the evolution of lyotropic liquid crystals (LLCs) in ocular drug delivery, focusing on their ability to address the challenges associated with traditional ophthalmic formulations. This study aims to underscore the enhanced bioavailability, prolonged retention, and controlled release properties of [...] Read more.

Background/Objectives: This review examines the evolution of lyotropic liquid crystals (LLCs) in ocular drug delivery, focusing on their ability to address the challenges associated with traditional ophthalmic formulations. This study aims to underscore the enhanced bioavailability, prolonged retention, and controlled release properties of LLCs that significantly improve therapeutic outcomes. Methods: This review synthesizes data from various studies on both bulk-forming LLCs and liquid crystal nanoparticles (LCNPs). It also considers advanced analytical techniques, including the use of machine learning and AI-driven predictive modeling, to forecast the phase behavior and molecular structuring of LLC systems. Emerging technologies in biosensing and real-time diagnostics are discussed to illustrate the broader applicability of LLCs in ocular health. Results: LLCs are identified as pivotal in promoting targeted drug delivery across different regions of the eye, with specific emphasis on the tailored optimization of LCNPs. This review highlights principal categories of LLCs used in ocular applications, each facilitating unique interactions with physiological systems to enhance drug efficacy and safety. Additionally, novel applications in biosensing demonstrate LLCs’ capacity to improve diagnostic processes. Conclusions: Lyotropic liquid crystals offer transformative potential in ocular drug delivery by overcoming significant limitations of conventional delivery methods. The integration of predictive technologies and biosensing applications further enriches the utility of LLCs, indicating a promising future for their use in clinical settings. This review points to continued advancements and encourages further research in LLC technology to maximize its therapeutic benefits. Full article

(This article belongs to the Topic Challenges and Opportunities in Drug Delivery Research)

► Show Figures

Figure 1

22 pages, 728 KiB

Open AccessEditor’s ChoiceReview

Lipid-Based Nanocarriers: Bridging Diagnosis and Cancer Therapy

by Alessandra Giordano, Anna Chiara Provenza, Giorgio Reverchon, Lucia Baldino and Ernesto Reverchon

Pharmaceutics 2024, 16(9), 1158; https://doi.org/10.3390/pharmaceutics16091158 - 1 Sep 2024

Cited by 10 | Viewed by 3294

Abstract

Theranostics is a growing field that matches diagnostics and therapeutics. In this approach, drugs and techniques are uniquely coupled to diagnose and treat medical conditions synergically or sequentially. By integrating diagnostic and treatment functions in a single platform, the aim of theranostics is [...] Read more.

Theranostics is a growing field that matches diagnostics and therapeutics. In this approach, drugs and techniques are uniquely coupled to diagnose and treat medical conditions synergically or sequentially. By integrating diagnostic and treatment functions in a single platform, the aim of theranostics is to improve precision medicine by tailoring treatments based on real-time information. In this context, lipid-based nanocarriers have attracted great scientific attention due to their biodegradability, biocompatibility, and targeting capabilities. The present review highlights the latest research advances in the field of lipid-based nanocarriers for cancer theranostics, exploring several ways of improving in vivo performance and addressing associated challenges. These nanocarriers have significant potential to create new perspectives in the field of nanomedicine and offer promise for a significant step towards more personalized and precise medicine, reducing side effects and improving clinical outcomes for patients. This review also presents the actual barriers to and the possible challenges in the use of nanoparticles in the theranostic field, such as regulatory hurdles, high costs, and technological integration. Addressing these issues through a multidisciplinary and collaborative approach among institutions could be essential for advancing lipid nanocarriers in the theranostic field. Such collaborations can leverage diverse expertise and resources, fostering innovation and overcoming the complex challenges associated with clinical translation. This approach will be crucial for realizing the full potential of lipid-based nanocarriers in precision medicine. Full article

(This article belongs to the Topic Challenges and Opportunities in Drug Delivery Research)

► Show Figures

Figure 1

17 pages, 5960 KiB

Open AccessArticle

The Cytoprotective Effect of C60 Derivatives in the Self-Microemulsifying Drug Delivery System against Triptolide-Induced Cytotoxicity In Vitro

by Beihua Xu, Zhenyu Wang, Huimin Zhang, Xiao Xu, Mengjie Tang, Gang Wang, Zhongpeng Ding, Ruihao Yu, Meihong Ding, Ting Zhang and Senlin Shi

Molecules 2024, 29(17), 4073; https://doi.org/10.3390/molecules29174073 - 28 Aug 2024

Cited by 1 | Viewed by 1145

Abstract

Objective: The aim of this study was to optimize the formulation of a C60-modified self-microemulsifying drug delivery system loaded with triptolide (C60-SMEDDS/TP) and evaluate the cytoprotective effect of the C60-SMEDDS/TP on normal human cells. Results: The C60-SMEDDS/TP exhibited rapid emulsification, an optimal particle [...] Read more.

Objective: The aim of this study was to optimize the formulation of a C60-modified self-microemulsifying drug delivery system loaded with triptolide (C60-SMEDDS/TP) and evaluate the cytoprotective effect of the C60-SMEDDS/TP on normal human cells. Results: The C60-SMEDDS/TP exhibited rapid emulsification, an optimal particle size distribution of 50 ± 0.19 nm (PDI 0.211 ± 0.049), and a near-neutral zeta potential of −1.60 mV. The release kinetics of TP from the C60-SMEDDS/TP exhibited a sustained release profile and followed pseudo-first-order release kinetics. Cellular proliferation and apoptosis analysis indicated that the C60-SMEDDS/TP (with a mass ratio of TP: DSPE-PEG-C60 = 1:10) exhibited lower toxicity towards L02 and GES-1 cells. This was demonstrated by a higher IC50 (40.88 nM on L02 cells and 17.22 nM on GES-1 cells) compared to free TP (21.3 nM and 11.1 nM), and a lower apoptosis rate (20.8% on L02 cells and 26.3% on GES-1 cells, respectively) compared to free TP (50.5% and 47.0%) at a concentration of 50 nM. In comparison to the free TP group, L02 cells and GES-1 cells exposed to the C60-SMEDDS/TP exhibited a significant decrease in intracellular ROS and an increase in mitochondrial membrane potential (ΔψM). On the other hand, the C60-SMEDDS/TP demonstrated a similar inhibitory effect on BEL-7402 cells (IC50 = 28.9 nM) and HepG2 cells (IC50 = 107.6 nM), comparable to that of the free TP (27.2 nM and 90.4 nM). The C60-SMEDDS/TP group also exhibited a similar intracellular level of ROS and mitochondrial membrane potential compared to the SMEDDS/TP and free TP groups. Method: Fullerenol-Grafted Distearoyl Phosphatidylethanolamine-Polyethylene Glycol (DSPE-PEG-C60) was synthesized and applied in the self-microemulsifying drug delivery system. The C60-SMEDDS/TP was formulated using Cremophor EL, medium-chain triglycerides (MCT), PEG-400, and DSPE-PEG-C60, and loaded with triptolide (TP). The toxicity and bioactivity of the C60-SMEDDS/TP were assessed using normal human liver cell lines (L02 cells), normal human gastric mucosal epithelial cell lines (GES-1 cells), and liver cancer cell lines (BEL-7402 cells and HepG2 cells). The production of reactive oxygen species (ROS) after the C60-SMEDDS/TP treatment was assessed using 2′,7′-dichlorofluorescein diacetate (DCFDA) staining. The alterations in mitochondrial membrane potential (ΔψM) were assessed by measuring JC-1 fluorescence. Conclusions: The cytoprotection provided by the C60-SMEDDS/TP favored normal cells (L02 and GES-1) over tumor cells (BEL-7402 and HepG2 cells) in vitro. This suggests a promising approach for the safe and effective treatment of TP. Full article

(This article belongs to the Topic Challenges and Opportunities in Drug Delivery Research)

► Show Figures

Figure 1

23 pages, 2788 KiB

Open AccessArticle

Design and Evaluation of Clove Oil-Based Self-Emulsifying Drug Delivery Systems for Improving the Oral Bioavailability of Neratinib Maleate

by Radhika Rajiv Mahajan, Punna Rao Ravi, Riya Kamlesh Marathe, Ajay Gorakh Dongare, Apoorva Vinayak Prabhu and Łukasz Szeleszczuk

Pharmaceutics 2024, 16(8), 1087; https://doi.org/10.3390/pharmaceutics16081087 - 19 Aug 2024

Cited by 1 | Viewed by 1850

Abstract

Neratinib maleate (NM), a tyrosine kinase inhibitor, is used in the treatment of breast cancer. NM is orally administered at a high dose of 290 mg due to its low solubility and poor dissolution rate at pH > 3, as well as gut-wall [...] Read more.

Neratinib maleate (NM), a tyrosine kinase inhibitor, is used in the treatment of breast cancer. NM is orally administered at a high dose of 290 mg due to its low solubility and poor dissolution rate at pH > 3, as well as gut-wall metabolism limiting its bioavailability. Self-emulsifying drug delivery systems (SEDDSs) of NM were developed in the current study to improve its oral bioavailability. The oily vehicle (clove oil) was selected based on the solubility of NM, while the surfactant and the cosurfactant were selected based on the turbidimetric analysis. Three different sets were screened for surfactant selection in the preparation of SEDDS formulations, the first set containing Cremophor^® EL alone as the surfactant, the second set containing a mixture of Cremophor^® EL (surfactant) and Caproyl^® PGMC (cosurfactant), and the third set containing a mixture of Cremophor^® EL (surfactant) and Capmul^® MCM C8 (cosurfactant). Propylene glycol was used as the cosolubilizer in the preparation of SEDDSs. A series of studies, including the construction of ternary phase diagrams to determine the zone of emulsification, thermodynamic stability studies (involving dilution studies, freeze-thaw, and heating–cooling studies), turbidimetric analysis, and physicochemical characterization studies were conducted to identify the two most stable combinations of SEDDSs. The two optimized SEDDS formulations, TP16 and TP25, consisted of clove oil (45% w/w) and propylene glycol (5% w/w) in common but differed with respect to the surfactant or surfactant mixture in the formulations. TP16 was prepared using a mixture of Cremophor^® EL (surfactant) and Caproyl^® PGMC (cosurfactant) in a 4:1 ratio (50% w/w), while TP25 contained only Cremophor^® EL (50% w/w). The mean globule sizes were 239.8 ± 77.8 nm and 204.8 ± 2.4 nm for TP16 and TP25, respectively, with an emulsification time of <12 s for both formulations. In vitro drug dissolution studies performed at different pH conditions (3.0, 4.5, 6.8) have confirmed the increase in solubility and dissolution rate of the drug by TP16 and TP25 at all pH conditions compared to plain NM. An oral pharmacokinetic study in female Wistar rats showed that the relative bioavailability (Frel) values of TP16 and TP25 over the plain NM were 2.18 (p < 0.05) and 2.24 (p < 0.01), respectively. Full article

(This article belongs to the Topic Challenges and Opportunities in Drug Delivery Research)

► Show Figures

Figure 1

22 pages, 6281 KiB

Open AccessArticle

Design, Synthesis, and Evaluation of Oleyl-WRH Peptides for siRNA Delivery

by Mrigank Shekhar Rai, Muhammad Imran Sajid, Jonathan Moreno, Keykavous Parang and Rakesh Kumar Tiwari

Pharmaceuticals 2024, 17(8), 1083; https://doi.org/10.3390/ph17081083 - 18 Aug 2024

Cited by 3 | Viewed by 2339

Abstract

Delivering nucleic acid therapeutics across cell membranes is a significant challenge. Cell-penetrating peptides (CPPs) containing arginine (R), tryptophan (W), and histidine (H) show promise for siRNA delivery. To improve siRNA delivery and silence a model STAT3 gene, we hypothesized that oleyl acylation to [...] Read more.

Delivering nucleic acid therapeutics across cell membranes is a significant challenge. Cell-penetrating peptides (CPPs) containing arginine (R), tryptophan (W), and histidine (H) show promise for siRNA delivery. To improve siRNA delivery and silence a model STAT3 gene, we hypothesized that oleyl acylation to CPPs, specifically (WRH)_n, would enhance STAT3 silencing efficiency in breast and ovarian cancer cells. Using Fmoc/tBu solid-phase peptide chemistry, we synthesized, purified, and characterized the oleyl-conjugated (WRH)_n (n = 1–4) peptides. The peptide/siRNA complexes were non-cytotoxic at N/P 40 (~20 μM) against MDA-MB-231, MCF-7, SK-OV-3, and HEK-293 cells after 72 h incubation. All peptide/siRNA complexes showed serum stability at N/P ≥ 40. The synthesized conjugates, with a diameter of <100 nm, formed nano-complexes with siRNA and exhibited a stable range of zeta potential values (13–18 mV at N/P = 40). Confocal microscopy and flow cytometry analysis provided qualitative and quantitative evidence of a successful cellular internalization of siRNA. The peptides oleyl-(WRH)₃ and oleyl-(WRH)₄ showed ~60% and ~75% cellular uptake of siRNA, respectively, in both MDA-MB-231 and SK-OV-3 cells. Western blot analysis of oleyl-(WRH)₄ demonstrated effective silencing of the STAT-3 gene, with ~75% silencing in MDA-MB-231 cells and ~45% in SK-OV-3 cells. Full article

(This article belongs to the Topic Challenges and Opportunities in Drug Delivery Research)

► Show Figures

Graphical abstract

33 pages, 835 KiB

Open AccessEditor’s ChoiceReview

Advances in Intrathecal Nanoparticle Delivery: Targeting the Blood–Cerebrospinal Fluid Barrier for Enhanced CNS Drug Delivery

by Ahmad Khalid Madadi and Moon-Jun Sohn

Pharmaceuticals 2024, 17(8), 1070; https://doi.org/10.3390/ph17081070 - 15 Aug 2024

Cited by 8 | Viewed by 3886

Abstract

The blood–cerebrospinal fluid barrier (BCSFB) tightly regulates molecular exchanges between the bloodstream and cerebrospinal fluid (CSF), creating challenges for effective central nervous system (CNS) drug delivery. This review assesses intrathecal (IT) nanoparticle (NP) delivery systems that aim to enhance drug delivery by circumventing [...] Read more.

The blood–cerebrospinal fluid barrier (BCSFB) tightly regulates molecular exchanges between the bloodstream and cerebrospinal fluid (CSF), creating challenges for effective central nervous system (CNS) drug delivery. This review assesses intrathecal (IT) nanoparticle (NP) delivery systems that aim to enhance drug delivery by circumventing the BCSFB, complementing approaches that target the blood–brain barrier (BBB). Active pharmaceutical ingredients (APIs) face hurdles like restricted CNS distribution and rapid clearance, which diminish the efficacy of IT therapies. NPs can be engineered to extend drug circulation times, improve CNS penetration, and facilitate sustained release. This review discusses key pharmacokinetic (PK) parameters essential for the effectiveness of these systems. NPs can quickly traverse the subarachnoid space and remain within the leptomeninges for extended periods, often exceeding three weeks. Some designs enable deeper brain parenchyma penetration. Approximately 80% of NPs in the CSF are cleared through the perivascular glymphatic pathway, with microglia-mediated transport significantly contributing to their paravascular clearance. This review synthesizes recent progress in IT-NP delivery across the BCSFB, highlighting critical findings, ongoing challenges, and the therapeutic potential of surface modifications and targeted delivery strategies. Full article

(This article belongs to the Topic Challenges and Opportunities in Drug Delivery Research)

► Show Figures

Figure 1

23 pages, 6456 KiB

Open AccessArticle

Slowing Down the “Magic Bullet”: Encapsulation of Imatinib in Fe-MOF for Cardiotoxicity Reduction and Improvement in Anticancer Activity

by Weronika Strzempek, Elżbieta Menaszek, Monika Papież and Barbara Gil

Molecules 2024, 29(16), 3818; https://doi.org/10.3390/molecules29163818 - 12 Aug 2024

Cited by 2 | Viewed by 1604

Abstract

Imatinib, a small molecule kinase inhibitor, is used as a cancer growth blocker. However, one of its most serious side effects is congestive cardiac failure. Reducing drug toxicity may be achieved through the use of drug delivery systems. Biocompatible metal-organic framework (MOF) materials, [...] Read more.

Imatinib, a small molecule kinase inhibitor, is used as a cancer growth blocker. However, one of its most serious side effects is congestive cardiac failure. Reducing drug toxicity may be achieved through the use of drug delivery systems. Biocompatible metal-organic framework (MOF) materials, namely FeMIL-100 and FeMIL-101-NH₂, were employed as potential imatinib carriers. They efficiently delivered the drug as an anticancer agent while minimizing cardiotoxicity. Notably, the release of imatinib from FeMIL-100 was rapid in acidic conditions and slower in pH-neutral environments, allowing targeted delivery to cancer cells. The carrier’s pH-dependent stability governed the drug release mechanism. Two release models—Korsmeyer–Peppas and Weibull—were fitted to the experimental data and discussed in terms of drug release from a rigid microporous matrix. Cytotoxicity tests were conducted on two cell lines: HL60 (a model cell line for acute myeloid leukemia) and H9c2 (a cell line for cardiomyocytes). Overall, the metal-organic framework (MOF) carriers mitigated imatinib’s adverse effects without compromising its effectiveness. Full article

(This article belongs to the Topic Challenges and Opportunities in Drug Delivery Research)

► Show Figures

Graphical abstract

23 pages, 1007 KiB

Open AccessReview

Edaravone for the Treatment of Motor Neurone Disease: A Critical Review of Approved and Alternative Formulations against a Proposed Quality Target Product Profile

by Riuna O’Neill, Okhee Yoo, Philip Burcham and Lee Yong Lim

Pharmaceutics 2024, 16(8), 993; https://doi.org/10.3390/pharmaceutics16080993 - 26 Jul 2024

Cited by 1 | Viewed by 2486

Abstract

Edaravone is one of two main drugs for treating motor neurone disease (MND). This review proposes a specific quality target product profile (QTPP) for edaravone following an appraisal of the issues accounting for the poor clinical uptake of the approved IV and oral [...] Read more.

Edaravone is one of two main drugs for treating motor neurone disease (MND). This review proposes a specific quality target product profile (QTPP) for edaravone following an appraisal of the issues accounting for the poor clinical uptake of the approved IV and oral liquid edaravone formulations. This is followed by a review of the alternative oral formulations of edaravone described in the published patent and journal literature against the QTPP. A total of 14 texts published by six research groups on 18 novel oral formulations of edaravone for the treatment of MND have been reviewed. The alternative oral formulations included liquid and solid formulations developed with cyclodextrins, lipids, surfactants, co-surfactants, alkalising agents, tablet excipients, and co-solvents. Most were intended to deliver edaravone for drug absorption in the lower gastrointestinal tract (GIT); however, there were also four formulations targeting the oral mucosal absorption of edaravone to avoid first-pass metabolism. All the novel formulations improved the aqueous solubility, stability, and oral bioavailability (BA) of edaravone compared to an aqueous suspension of edaravone. A common limitation of the published formulations is the lack of MND-patient-centred data. Except for TW001, no other formulations have been trialled in MND patients. To meet the QTPP of an oral edaravone formulation for MND patients, it is recommended that a tablet of appropriate size and with acceptable taste and stability be designed for the effective sublingual or buccal absorption of edaravone. This tablet should be designed with input from the MND community. Full article

(This article belongs to the Topic Challenges and Opportunities in Drug Delivery Research)

► Show Figures

Figure 1

15 pages, 7635 KiB

Open AccessArticle

Enhanced Cellular Doxorubicin Uptake via Delayed Exposure Following Nanosecond Pulsed Electric Field Treatment: An In Vitro Study

by Rongwei Ma, Yubo Wang, Zhihao Wang, Shengyong Yin, Zhen Liu and Keping Yan

Pharmaceutics 2024, 16(7), 851; https://doi.org/10.3390/pharmaceutics16070851 - 24 Jun 2024

Viewed by 1199

Abstract

The combination of nanosecond Pulsed Electric Field (nsPEF) with pharmaceuticals is a pioneering therapeutic method capable of enhancing drug uptake efficacy in cells. Utilizing nsPEFs configured at 400 pulses, an electric field strength of 15 kV/cm, a pulse duration of 100 ns, and [...] Read more.

The combination of nanosecond Pulsed Electric Field (nsPEF) with pharmaceuticals is a pioneering therapeutic method capable of enhancing drug uptake efficacy in cells. Utilizing nsPEFs configured at 400 pulses, an electric field strength of 15 kV/cm, a pulse duration of 100 ns, and a repetition rate of 10 pulses per second (PPS), we combined the nsPEF with a low dose of doxorubicin (DOX) at 0.5 μM. Upon verifying that cells could continuously internalize DOX from the surrounding medium within 1 h post nsPEF exposure, we set the DOX exposure period to 10 min and contrasted the outcomes of varying sequences of DOX and nsPEF administration: pulsing followed by DOX, DOX followed by pulsing, and DOX applied 40 min after pulsing. Flow cytometry, CCK-8 assays, and transmission electron microscopy (TEM) were employed to examine intracellular DOX accumulation, cell viability, apoptosis, cell cycle, and ultrastructural transformations. Our findings demonstrate that exposing cells to DOX 40 min subsequent to nsPEF treatment can effectively elevate intracellular DOX levels, decrease cell viability, and inhibit the cell cycle. This research work presents a novel approach to enhance DOX uptake efficiency with moderate conditions of both DOX and nsPEF. Full article

(This article belongs to the Topic Challenges and Opportunities in Drug Delivery Research)

► Show Figures

Figure 1

10 pages, 1405 KiB

Open AccessReview

Non-Analog Compounds to Sialic Acid as Inhibitors of Influenza Virus Neuraminidase: An Underexplored Approach for Novel Antivirals―Systematic Review

by Luis Márquez-Domínguez, Carolina Jasso-Miranda, Virginia Sedeño-Monge and Gerardo Santos-López

Sci. Pharm. 2024, 92(2), 33; https://doi.org/10.3390/scipharm92020033 - 19 Jun 2024

Viewed by 2405

Abstract

Influenza poses a significant threat to public health worldwide, particularly among vulnerable populations such as children, the elderly, immunocompromised individuals, and those with chronic diseases. It is associated with high mortality and morbidity rates. Neuraminidase inhibitors play a crucial role in influenza treatment [...] Read more.

Influenza poses a significant threat to public health worldwide, particularly among vulnerable populations such as children, the elderly, immunocompromised individuals, and those with chronic diseases. It is associated with high mortality and morbidity rates. Neuraminidase inhibitors play a crucial role in influenza treatment by mitigating the risk of complications and death. However, the genetic variability of the influenza virus enables the emergence of drug-resistant mutations. This review focuses on the search for new compounds that are not analogous to sialic acid, aiming to inhibit the activity of viral neuraminidase in vitro, viral replication in cell cultures, or animal models. Influenza virus strains that have been reported in the literature present specific mutations that generate resistance to neuraminidase inhibitors. Since these inhibitors bear structural resemblance to sialic acid, the predominant location for these mutations is the enzyme’s active site. Consequently, exploring alternative compound classes becomes imperative to circumvent this interaction pattern. These compounds will introduce diverse molecular frameworks, serving as foundational structures for further development through rational drug design, thereby engendering novel antiviral agents targeting influenza. The potential prospects for developing novel influenza antivirals based on these findings are discussed. Full article

(This article belongs to the Topic Challenges and Opportunities in Drug Delivery Research)

► Show Figures

Figure 1

14 pages, 12746 KiB

Open AccessArticle

Adenosine Encapsulation and Characterization through Layer-by-Layer Assembly of Hydroxypropyl-β-Cyclodextrin and Whey Protein Isolate as Wall Materials

by Yudie Jin and Suning Zhang

Molecules 2024, 29(9), 2046; https://doi.org/10.3390/molecules29092046 - 29 Apr 2024

Cited by 5 | Viewed by 1795

Abstract

Adenosine, as a water-soluble active substance, has various pharmacological effects. This study proposes a layer-by-layer assembly method of composite wall materials, using hydroxypropyl-

β

-cyclodextrin as the inner wall and whey protein isolate as the outer wall, to encapsulate adenosine within the core [...] Read more.

Adenosine, as a water-soluble active substance, has various pharmacological effects. This study proposes a layer-by-layer assembly method of composite wall materials, using hydroxypropyl-

β

-cyclodextrin as the inner wall and whey protein isolate as the outer wall, to encapsulate adenosine within the core material, aiming to enhance adenosine microcapsules’ stability through intermolecular interactions. By combining isothermal titration calorimetry with molecular modeling analysis, it was determined that the core material and the inner wall and the inner wall and the outer wall interact through intermolecular forces. Adenosine and hydroxypropyl-

β

-cyclodextrin form an optimal 1:1 complex through hydrophobic interactions, while hydroxypropyl-

β

-cyclodextrin and whey protein isolate interact through hydrogen bonds. The embedding rate of AD/Hp-

β

-CD/WPI microcapsules was 36.80%, and the 24 h retention rate under the release behavior test was 76.09%. The method of preparing adenosine microcapsules using composite wall materials is environmentally friendly and shows broad application prospects in storage and delivery systems with sustained release properties. Full article

(This article belongs to the Topic Challenges and Opportunities in Drug Delivery Research)

► Show Figures

Graphical abstract

Topic Menu

Topic Editors

Challenges and Opportunities in Drug Delivery Research

Topic Information

Keywords

Participating Journals

Published Papers (15 papers)

Further Information

Guidelines

MDPI Initiatives

Follow MDPI

Topic Menu

Topic Editors

Challenges and Opportunities in Drug Delivery Research

Topic Information

Keywords

Participating Journals

Related Topic

Published Papers (15 papers)

Further Information

Guidelines

MDPI Initiatives

Follow MDPI